Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Insulin Like Growth Factor I - Drugs In Development, 2022'; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin. It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling.

The report 'Insulin Like Growth Factor I - Drugs In Development, 2022' outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Metabolic Disorders, Musculoskeletal Disorders and Ophthalmology which include indications Neuropathic Pain (Neuralgia), Acute Ischemic Stroke, Age Related Macular Degeneration, Amyotrophic Lateral Sclerosis, Breast Cancer, Diabetic Retinopathy, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Parkinson's Disease, Peripheral Nerve Injury, Peripheral Neuropathy (Sensory Neuropathy), Prostate Cancer, Retinal Vein Occlusion, Sarcopenia and Solid Tumor.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)
• The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope